Venus thromboembolism (VTE), also known as blood clots, is the leading cause of unnecessary hospital deaths in the United States, and scientists have spent a long time trying to find the cause.
According to a new study published in Blood Advances, people with cancer who are non-O blood groups, such as A, B, and AB, were more likely to have thromboembolism (VTE) or blood clots in the veins. A few months after the diagnosis.
To identify patients at high risk for VTE, existing assessments include features such as the type of tumor or cancer. Nevertheless, many people who do not have this condition develop life-threatening blood clots that go unnoticed.
Deep-vein thrombosis (DVT), a blood clot that usually occurs in the deep veins of the legs, and pulmonary embolism (PE), a life-threatening illness that occurs when blood clots break and accumulate in the pulmonary arteries. Both examples of VTE. Although blood clots can harm anyone, evidence shows that blood groups other than O are more likely to have VTE. Cancer and cancer treatments increase the risk of blood clots, and while people with more serious cancers are more likely to have VTE, there is less data on the risk in patients with cancer who are not associated with thrombosis.
The researchers looked at the effects of non-O blood group on the development of VTE in study participants. They used the Vienna Cancer and Thrombosis Study (CATS) data set to collect data on 1,708 adult participants with new or recurrent cancer diagnoses. Participants were divided into groups based on their blood type, then further divided into groups based on their tumor classification. Patients with tumors of the pancreas, stomach and brain are considered to be at a significant risk. Although the type of tumor can help identify patients who are more prone to VTE, many people with less severe tumors suffer from dangerous blood clots that require more monitoring and treatment. The results of the study show that blood type can be another effective predictor.
“We know that the type of tumor helps determine the baseline risk of VTE. But we see that this risk assessment fails to catch all cancer patients who may have this blood clot, ”said study author Cornelia English. “By simply diagnosing the type of tumor, we miss up to 50% of VTE developers.”
Patients in non-O blood groups were more likely to develop VTE three months after the cancer was diagnosed or recurred, according to their results. According to Dr. English, this link was not clear at the time of diagnosis, as cancer drugs increased the risk of blood clots, giving a less relevant prediction of VTE on blood type in the early stages of treatment. Patients with non-O blood groups with tumors outside the high-risk segment were more likely to have blood clots regardless of time, indicating that many patients may develop fractures by relying solely on the type of tumor to determine VTE risk.
Although innovative, these results, said. According to English, investigative and further research is needed. Researchers want to know more about future biological processes based on these discoveries. They believe that in the future, blood type will be useful in assessing the risk of cancer-related VTE.
“Blood typing is easy, can be done globally, and does not require any special background knowledge or tools,” added Dr. English. “And of course, every risk factor we identify helps our cancer patients better understand these life-threatening complications. Perhaps it will raise awareness of the role that blood groups can play as clinical biomarkers.”
Image Credit: Getty
You read: This blood group is the most exposed to blood clots in people with cancer